Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di Entrectinib (Rxdx-101) in bambini e adolescenti con tumori del SNC localmente avanzati o metastatici solidi o primari e/o che non hanno opzioni terapeutiche soddisfacenti (STARTRK-NG)

18 settembre 2026 aggiornato da: Hoffmann-La Roche

Uno studio di fase 1/2, in aperto, di aumento della dose e di espansione di Entrectinib (Rxdx-101) in pediatria con tumori del SNC solidi o primari localmente avanzati o metastatici e/o che non hanno opzioni terapeutiche soddisfacenti

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

69

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
      • Beijing, Cina
        • Beijing Children's Hospital, Capital Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200082
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
      • Lyon, Francia, 69373
        • Centre Leon Berard
      • Marseille, Francia, 13385
        • Hôpital de la Timone, Oncologie Pédiatrique
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Germania, 69120
        • Universitaetsklinikum Heidelberg
      • Hong Kong, Hong Kong, 00000
        • Hong Kong Children's Hospital
    • Lombardy
      • Milan, Lombardy, Italia, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • London, Regno Unito, SW3 6JJ
        • Royal Marsden Hospital (Sutton)
      • Newcastle upon Tyne, Regno Unito, NE1 4LP
        • Royal Victoria Infirmary
      • Madrid, Spagna, 28009
        • Hospital Infantil Universitario Nino Jesus
    • California
      • La Jolla, California, Stati Uniti, 92093-0706
        • University of California San Diego
      • San Francisco, California, Stati Uniti, 94158
        • UCSF Benioff Children's Hospital
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Egleston Children's Hospital at Emory University Atlanta
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • University of Chicago
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21205
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Dana Farber Cancer Institute
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University,St. Louis Children's Hospital
    • New York
      • New York, New York, Stati Uniti, 10065
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43205
        • Nationwide Children's Hospital
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Oregon Health & Science Uni
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis, Tennessee, Stati Uniti, 38105
        • St. Jude Children'S Research Hospital
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Texas Children's Cancer and Hematology Center
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84113
        • Primary Children's Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 1 secondo a 18 anni (Bambino, Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Disease status:

    • Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1

    • Phase 2 portion:

      • Part B: Participants must have measurable or evaluable disease, as defined by RANO
      • Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
      • Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
      • Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
  2. Tumor type:

    • Phase 1 portion:

      * Part A: Relapsed or refractory extracranial solid tumors

    • Phase 2 portion

      • Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
      • Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
  3. Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse

  4. Archival tumor tissue from diagnosis or, preferably, at relapse

  5. Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks

  6. Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive

  7. Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment

  8. Adequate organ and neurologic function

  9. Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.

  10. For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug

Exclusion Criteria:

  1. Receiving other experimental therapy
  2. Known congenital long QT syndrome
  3. History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
  4. Known active infections
  5. Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
  6. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
  7. Prior treatment with approved or investigational TRK or ROS1 inhibitors
  8. Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
  9. Patients with NB with bone marrow space-only disease
  10. Incomplete recovery from acute effects of any surgery prior to treatment.
  11. Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
  12. Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Extracranial solid tumors harboring NTRK1/2/3,

Arm closed for further enrollment

ROS1, ALK non-gene fusion molecular alterations

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Altri nomi:
  • RXDX-101
Comparatore attivo: CNS tumors harboring- NTRK1/2/3, ROS1, ALK

Arm closed for further enrollment

molecular alterations, including gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Altri nomi:
  • RXDX-101
Comparatore attivo: Neuroblastoma

Arm closed for further enrollment

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Altri nomi:
  • RXDX-101
Comparatore attivo: Non-neuroblastoma, extracranial solid tumors

Arm closed for further enrollment

harboring - NTRK1/2/3, ROS1, ALK gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Altri nomi:
  • RXDX-101
Comparatore attivo: Any participant unable to swallow capsules

Arm closed for further enrollment

Any participant who otherwise meet all other eligibility criteria

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Altri nomi:
  • RXDX-101
Comparatore attivo: Expansion: CNS tumors harboring NTRK1/2/3, ROS1

gene fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Altri nomi:
  • RXDX-101
Comparatore attivo: Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1

NTRK 1,2,3 and ROS1 fusions

Oral entrectinib (RXDX-101)

TRKA/B/C, ROS1, and ALK inhibitor

Altri nomi:
  • RXDX-101

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Maximum Tolerated Dose (MTD)
Lasso di tempo: Approximately 6 months

Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03)

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Lasso di tempo: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Lasso di tempo: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
Lasso di tempo: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
Lasso di tempo: Approximately 6 months

Assessed by NCI CTCAE v4.03

Approximately 6 months
Cohort B: Objective Response Rate (ORR)
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR

Approximately 6 months
Cohort D: ORR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR

Approximately 6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
Lasso di tempo: Approximately 24 months

AE, ECG and Labs assessed by NCI CTCAE v4.03

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F1 Formulation
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Time to Cmax, by inspection (Tmax) using minitablets/F15
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F1 Formulation
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
AUC at steady state (AUCss) using minitablets/F15
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F1 Formulation
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Terminal half life (t½) using minitablets/F15
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F1 Formulation
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Area under the drug concentration by time curve (AUC) using minitablets/F15
Lasso di tempo: Approximately 24 months

Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter

Approximately 24 months
Cohort A, D, or E: Clinical Benefit Rate (CBR)
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: CBR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: CBR
Lasso di tempo: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Progression-free Survival (PFS)
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: PFS
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: PFS
Lasso di tempo: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Overall Survival (OS)
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1

Approximately 6 months
Cohort B or E: OS
Lasso di tempo: Approximately 6 months

Assessed by RANO

Approximately 6 months
Cohort A, D, or E: ORR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: ORR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: ORR
Lasso di tempo: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Time to response (TTR)
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: TTR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: TTR
Lasso di tempo: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Cohort A, D, or E: Duration of Response (DOR)
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Cohort B or E: DOR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Cohort C: DOR
Lasso di tempo: Approximately 6 months

Assessed by the Curie scale per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
Lasso di tempo: Approximately 6 months

Assessed by RECIST v1.1 per the BICR and investigator

Approximately 6 months
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Lasso di tempo: Approximately 6 months

Assessed by RANO per the BICR and investigator

Approximately 6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Clinical Trials, Hoffmann-La Roche

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

3 maggio 2016

Completamento primario (Stimato)

30 giugno 2027

Completamento dello studio (Stimato)

30 giugno 2027

Date di iscrizione allo studio

Primo inviato

4 gennaio 2016

Primo inviato che soddisfa i criteri di controllo qualità

7 gennaio 2016

Primo Inserito (Stimato)

8 gennaio 2016

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

18 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • RXDX-101-03
  • CO40778 (Altro identificatore: Hoffmann-La Roche)
  • 2023-505088-35-00 (Ctis)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .